FDA recall record

Pharmedium Services NORepinephrine Bitartrate 8 mg added to 500 mL 5% Dextrose Injection USP recall — FDA D-0626-2020

Subpotent Drug

Class IIIclassification
D-0626-2020official record ID
Jan 1, 2020report date

Recall record at a glance

Official recordD-0626-2020
CategoryDrug Recalls
ClassificationClass III
FDA record statusTerminated
Recalling firmPharmedium Services, LLC
Report dateJan 1, 2020
Recall initiation dateDec 16, 2019
Quantity864 bags
LocationLake Forest, IL, United States

Official product description

NORepinephrine Bitartrate 8 mg added to 500 mL 5% Dextrose Injection USP (16 mcg per mL) Total Volume 508.00 mL Viaflex Bag, High Alert, Rx Only, PharMEDium Services LLC., 12620 W Airport Blvd #130 Sugar Land, TX 77478.

Why the product was recalled

Subpotent Drug

Distribution information

Nationwide in the U.S.

How to read the classification

FDA Class III generally covers situations in which use of or exposure to the product is not likely to cause adverse health consequences. The classification displayed here is taken from the FDA enforcement record.

Additional record details

Recall type: Voluntary: Firm initiated. Initial notification: Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit.

What to do next

If you believe you have the recalled product, use the recall number and firm information above to confirm the official notice and follow the instructions issued by the FDA, recalling firm, retailer or product manufacturer. For drugs and medical devices, decisions about treatment or medical care should be discussed with a qualified health professional.

About this record

Recall Lookup USA preserves the most complete source information successfully retrieved. We do not create missing facts or infer affected lots or VINs. The official record may still change, so use the identifier above when verifying current instructions.

FDA source limitation: openFDA enforcement reports are a reference dataset, not a live public-alert or recall-lifecycle service. FDA notes that enforcement-report status may not be updated after classification. Confirm current actions with the FDA, recalling firm or appropriate healthcare professional when relevant.

Related recall records

Other records from the same recalling company are shown first when available.